

Resource Summary Report

Generated by [RRID](#) on Sep 1, 2026

OVCA420

RRID:CVCL_3935

Type: Cell Line

Proper Citation

RRID:CVCL_3935

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3935

Proper Citation: RRID:CVCL_3935

Description: Cell line OVCA420 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Ovarian serous adenocarcinoma

Defining Citation: [PMID:1536252](#), [PMID:6346879](#), [PMID:7028788](#), [PMID:10318951](#), [PMID:10972993](#), [PMID:11793438](#), [PMID:12960427](#), [PMID:20204287](#), [PMID:22115851](#), [PMID:22710073](#), [PMID:23415752](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28273451](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:35839778](#)

Comments: Population: African American., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OVCA420

Synonyms: OVCA 420, OvCa 420, OVCA-420, OVCAR-420, OVCAR 420, OVCAR420

Cross References: BTO:BTO_0002563, EFO:EFO_0006720, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:980, BioSample:SAMN03471874, cancercellines:CVCL_3935, Cell_Model_Passport:SIDM00967, Cosmic:924145, Cosmic:927566, Cosmic-CLP:1480364, DepMap:ACH-002181, EGA:EGAS00001000610,

EGA:EGAS00001000978, GDSC:1480364, GEO:GSM659390, GEO:GSM711703, GEO:GSM851928, GEO:GSM1340585, GEO:GSM1341130, GEO:GSM1670315, GEO:GSM2474990, IARC_TP53:28490, PharmacDB:OVCA420_1213_2019, PRIDE:PXD030304, Wikidata:Q54936981

ID: CVCL_3935

Record Creation Time: 20220427T221403+0000

Record Last Update: 20260829T235526+0000

Ratings and Alerts

No rating or validation information has been found for OVCA420.

No alerts have been found for OVCA420.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Tong J, et al. (2026) p53 and fatty acids collaborate to trigger ferroptosis via the FBXO2-FABP5 axis in colorectal cancer. Redox biology, 90, 104043.

Zeng Z, et al. (2026) Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer. British journal of cancer, 134(12), 1830.

Nguyen LL, et al. (2024) Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation. Molecular cancer therapeutics, 23(9), 1332-1347.

Narayanan A, et al. (2024) A novel ITGB8 transcript variant sustains ovarian cancer cell survival through genomic instability and altered ploidy on a mutant p53 background. Journal of ovarian research, 17(1), 218.

Furutake Y, et al. (2024) YAP1 Suppression by ZDHHC7 Is Associated with Ferroptosis Resistance and Poor Prognosis in Ovarian Clear Cell Carcinoma. Molecular cancer therapeutics, 23(11), 1652.

McMellen A, et al. (2023) ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer. Molecular cancer research : MCR, 21(1), 3.

Jiang W, et al. (2023) A NOTCH1 Mutation Found in a Newly Established Ovarian Cancer Cell Line (FDOVL) Promotes Lymph Node Metastasis in Ovarian Cancer. International journal of molecular sciences, 24(6).

Nguyen LL, et al. (2023) Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models. bioRxiv : the preprint server for biology.